IDYA (IDEAYA Biosciences) Earnings growth in current year

Official company branding of ideayabio.com (IDYA)

The reliability of cold chain drug delivery provides the foundation for IDEAYA Biosciences (IDYA), as evidenced by the year-over-year changes in EPS, where the indicator value stands at -268.90. Growth prospects rely on adherence to bioethics and environmental standards, although the high cost of clinical trials and dependence on patent protection, which determines future business sustainability, remain significant challenges.

IDYA (IDEAYA Biosciences, Inc.) Earnings growth in current year history from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for IDEAYA Biosciences (IDYA)

- share price and expert price forecast:
Price IDEAYA Biosciences Inc|IDYA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization IDEAYA Corp|IDYA - Total Company Value
- book capitalization data:
Accounting Value of a Share IDEAYA Biosciences|IDYA - Book Capitalization|Market Value to Equity Ratio ideayabio.com|IDYA - Company Total Assets
- debt and liquidity details:
Debt to Capital IDEAYA Biosciences|IDYA - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio ideayabio.com|IDYA - Company Aggregate Debts|Debts to Book Value IDEAYA Corp|IDYA - Company Long-Term Debts|Company Short-Term Indebtedness IDEAYA Biosciences|Intermediate Coverage Ratio ideayabio.com
- net income and valuation multiples indicators:
IDYA - Net Income|Future Net Profit IDEAYA Biosciences|IDYA - P/E Multiple|Future Price to Earnings Multiple IDEAYA Corp|IDYA - PEG Multiple|Company Value to EBITDA IDEAYA Corp|IDYA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year IDEAYA Biosciences|IDYA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth ideayabio.com|IDYA - Earnings per share growth in current year|Net earnings per share change forecast for next year IDEAYA Biosciences
- sales volume and revenue information:
IDYA - Company Sales|Company Expected Sales Volume IDEAYA Biosciences Inc|IDYA - P/S Multiple|Market Cap to Expected Sales Ratio IDEAYA Corp
Fundamental valuation:IDYA IDEAYA Biosciences Inc
Signature product of IDEAYA Corp

This indicator measures the year-over-year earnings per share (EPS) dynamics, allowing investors to assess the actual efficiency of value generation while filtering out short-term market noise. By analyzing the annual EPS growth trend with a value of -268.90, one can gauge the monetization potential of IDEAYA Biosciences patents through licensing or the mass production of targeted therapies.

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Corp) - Earnings growth in current year|Earnings growth in current year Nuvalent Therapeutics|Earnings per share growth in current year Kymera Therapeutics (KYMR)|ELVN (enliventherapeutics.com) - Earnings per share increase in current year|Earnings growth in current year ORIC (ORIC Pharmaceuticals, Inc.)|Net earnings per share change in current year Relay Therapeutics Inc|Nurix Pharma - Earnings growth in current year|Earnings per share growth rate in current year Tyra Corp|VSTM (Verastem, Inc.) - Net earnings per share growth this year|GLUE: Net earnings per one share growth for the current year|CGEM (Cullinan Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Immuneering Corp IMRX|Earnings growth in current year CCCC|Black Diamond Therapeutics, Inc - Earnings per share growth this year|Repare Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year PMVP|KPTI: Net earnings per share growth this year|Propanc Biopharma Inc - Net earnings per one share growth for the current year|BGMS: Earnings growth in current year|Aadi Bioscience, Inc. - Earnings per share increase in current year|ALRN (Aileron Therapeutics Inc) - Earnings growth in current year|Earnings per share growth rate in current year Blueprint Medicines Corp BPMC|Earnings per share growth in current year GlycoMimetics, Inc. (GLYC)|SWTX (SpringWorks Therapeutics Inc.) - Earnings per share increase in current year